

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA**

**Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over**

**Batch 91**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes, stakeholders identified the following potential equality issues:

- The EASI might underestimate the severity of atopic dermatitis in people with brown or black skin
- The DLQI may not account for anxiety and depression
- Consideration should be given to adolescents as a specific group as they may require higher levels of support and education to successfully manage their eczema.
- Consideration should be given to patient groups living in rural areas or those on low incomes if the treatment requires frequent hospital visits, particularly to central sites. Families may be unable to cover travel costs making the treatment inaccessible for them.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The experiences of all people of the condition will be taken into account by the appraisal committee. The committee cannot make separate recommendations for populations based solely on age or location and this is not considered an equality issue.

In accordance with NICE's [social value judgement](#) principles, no priority is given

based on individuals' income, social class, position in life or social roles in guidance developed for the NHS. NICE's standard approach to economic modelling (the 'reference case') does not compare NHS healthcare with privately funded healthcare.

The committee should take into account skin colour and how this could affect the assessment of the severity of atopic dermatitis and response to treatment.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

**Approved by Associate Director (name):** Emily Crowe

**Date:** 31 August 2023